How much does the third generation targeted drug Osimertinib cost?

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It has been marketed in China and is included in medical insurance. Patients can go to local hospital pharmacies to consult and purchase it by themselves. The latest price of this drug in China is about 4000-7000 yuan. At the same time, there are also legally marketed generic drugs in Laos and Bangladesh. Their drug ingredients are basically the same as the original drugs. The latest price is about a few hundred yuan, and the most expensive ones may reach one or two thousand yuan.

On February 16, 2024, the Food and Drug Administration approved osimertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy. These patients' tumors have EGFR exon 19 deletions or exon 21 L858R mutations, which must be detected by an FDA-approved test.

For this study, FLAURA 2 was conducted Evaluation of (NCT04035486), an open-label randomized trial involving 557NameEGFRExon19Deletion or exon21 L858Rmutation-positiveNSCLC patients who have not received prior systemic treatment for advanced disease. Patients were randomly assigned in a 1:1 ratio to receive platinum-based osimertinib plus chemotherapy or osimertinib monotherapy.

The primary efficacy outcome measure of the study is investigator-assessed progression-free survival (PFS), and overall survival (OS) is a key secondary outcome measure. Compared with osimertinib monotherapy, osimertinib combined with platinum-based chemotherapyPFS showed a statistically significant improvement, with a hazard ratio of 0.62 (95% confidence interval[CI]: 0.49, 0.79; bilateral p value < 0.0001). The median progression-free survival was 25.5 months (95% CI: 24.7, not estimable[NE]) and 16.7 months (95% CI: 14.1, 21.3).